Skip to content
lifestyle.claritypointe.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Spyre Therapeutics, Inc.
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
August 25, 2026
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
August 10, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
August 7, 2026
Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 4, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
June 5, 2026
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
June 3, 2026
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
May 27, 2026
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 5, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
May 1, 2026
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
April 16, 2026
1
2
Next Page
→